Genegoggle is a biotechnology company that utilizes multi-dimensional genomic and epigenetic analysis to develop precision therapeutics targeting cancer cells while minimizing damage to healthy tissues. Their Genegoggle Epigenetic Viewer (GEV) enables detailed visualization of DNA structures and epigenetic modifications, facilitating the identification of therapeutic targets and enhancing drug discovery processes.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often lack precision, damaging healthy tissues alongside cancerous cells due to a limited understanding of the epigenetic factors driving cancer development. Traditional methods primarily focus on the 2% of the genome that constitutes genes, neglecting the crucial regulatory role of the remaining 98%. This can lead to ineffective treatments and unintended side effects.
Solution
Genegoggle is developing precision therapeutics by leveraging multi-dimensional genomic and epigenetic analysis to target cancer cells while minimizing harm to healthy tissues. Their Genegoggle Epigenetic Viewer (GEV) enables detailed visualization of DNA structures and epigenetic modifications, facilitating the identification of novel therapeutic targets. GEV allows researchers to inspect the shape of DNA as it is packaged in the cell nucleus, acting as an epigenetic microscope for 3D DNA structure analysis. By integrating biomedical approaches with AI, Genegoggle aims to expand the current standard of care in precision medicine.
Target Audience
Genegoggle's primary customers are researchers and clinicians in the field of precision medicine, particularly those focused on cancer therapeutics and diagnostics.
Features
- Genegoggle Epigenetic Viewer (GEV) for visualizing and inspecting DNA structure within the cell nucleus.
- 3D DNA structure analysis to identify epigenetic modifications.
- Ability to compare various cell types and measure distances between genomic regions of interest.
- Identification of gene editing targets.
- DNA damage inspection capabilities.
- Facilitates selective drug activation.
- AI-powered analysis of multi-omic data for target discovery.